Clinical Trials Logo

Chronic Myeloid Leukemia clinical trials

View clinical trials related to Chronic Myeloid Leukemia.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT03348033 Enrolling by invitation - Clinical trials for Chronic Myeloid Leukemia

Safety and Feasibility of the Use of Natural Killer Cells in Patients With Chronic Myeloid Leukemia

Start date: March 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate safety, feasibility and maximum tolerated dose of NK cells cultured in vitro as adjuvant treatment of patients with chronic myeloid leukemia candidates to allogenic bone marrow transplantation or refractory to conventional treatment.

NCT ID: NCT00965224 Enrolling by invitation - Multiple Myeloma Clinical Trials

Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma

Start date: January 2010
Phase: Phase 2
Study type: Interventional

Dendritic cell therapy is a promising strategy for adjuvant cancer therapy in the setting of minimal residual disease (MRD) to fight off cancer relapse and/or progression. The investigators already performed a phase I safety study in leukemia patients that were in complete remission demonstrating the absence of side effects and feasibility of the therapy. Here, the investigators want to extend on this strategy by studying the clinical efficacy of autologous DC vaccination in patients with acute and chronic myeloid leukemia and myeloma patients. Effects of DC therapy on the immune reactivity towards leukemia cells as well as clinical parameters such molecular MRD monitoring, time to relapse (TTR), progression-free survival (PFS) and overall survival(OS) will be studied in vaccinated and non-vaccinated (control) patients. Patients will be vaccinated using their own dendritic cells electroporated with mRNA coding for the full-length Wilms' tumor antigen WT1.